Team

YFountain was founded by biotechnology professor/scientist from The University of California, San Francisco (UCSF). Our professional team include:

Inventors of the innovative, patent pending technology of High-Throughput Screening for Anti-Aging Substances.

Management professional with experiences in biotech research, business finance, administration and compliance.

Pharmaceutical chemist with experiences in translational process, guiding the early stage discoveries through animal tests and clinical trials, and for eventual application in human therapeutic treatments.

Professionals with expertise in artificial intelligence, computational biology and bioinformatics.


	Hao Li, Ph.D. Co-Founder & Patent Inventor Professor, Biochemistry and Biophysics, UCSF Director, Hillblom Center for the Biology of Aging, UCSF Investigator, CZ Biohub Dr. Li received his Ph.D. in theoretical physics from MIT, and has over 20 years of experience leading a research team focusing on bioinformatics, systems biology and aging. Dr. Li developed the first microfluidic system to analyze aging in single cells, and is the primary inventor of the high-throughput microfluidic single-cell analysis chip. Having published ~90 peer reviewed papers, Dr. Li leads research programs supported by NIH, Packard foundation, Hillblom foundation, and CZ Biohub. Dr. Li serves as the advisory board member of Max Planck Society, American Federation for Aging Research, and Member of the Faculty of 1000.
	Changhui Deng, Ph.D. Co-Founder & Patent Inventor Associate Professional Researcher, Biochemistry and Biophysics, UCSF Dr. Deng received his Ph.D. in biochemistry and molecular biology, UC Riverside. An expert in genetics and molecular biology, Dr. Deng developed the daughter arresting program (DAP) that forms the basis of high-throughput screening platform. Dr. Deng has published 13 peer reviewed papers and holds two US patents (pending).
	Allen Shen, Ph.D. Co-Founder & Chief Executive Officer Ph.D. of Microbiology, M.Sc. of Neuroscience Dr. Allen Shen is a multidisciplinary scientist and entrepreneur with a Ph.D. in Microbiology and an M.Sc. in Neuroscience. Driven by a passion for transforming scientific innovation into clinically meaningful and commercially translatable products, he co-founded YFountain and leads the company as Chief Executive Officer. Before cofounding YFountain, Dr. Shen established XAIGene Biotechnology, a platform company pioneering the integration of artificial intelligence and translational medicine. He previously held leadership and scientific roles at OBiO Technology, Kriya Therapeutics, Sangamo Therapeutics, and the University of Pennsylvania Gene Therapy Program, where he contributed to key initiatives in R&D, platform development, and strategic partnerships. Dr. Shen’s career embodies a distinctive blend of scientific rigor, entrepreneurial vision, and cross-sector leadership spanning biotechnology, AI, and clinical translation. He continues to lead YFountain’s mission to accelerate data-driven longevity innovation and the commercialization of next-generation health solutions.
	Yun Bai, Ph.D. Chief Financial Officer Microbiologist Dr. Bai received his Ph. D. from Columbia University in the field of budding yeast research and DNA repair. Besides biological research, Dr. Bai had also worked in the financial industry at Lehman Brothers and JP Morgan Chase, and has a multitude of expertise in biotech research, finance and compliance.
	Michelle Arkin, Ph.D. Scientific Advisor Professor and Chair, Pharmaceutical Chemistry, UCSF Co-Director, Small Molecule Discovery Center, UCSF Dr. Arkin is the Thomas William and Frederick John MacWilliam Distinguished Professor. Dr. Arkin serves as the Chair of Pharmaceutical Chemistry at UCSF, and is the co-Director of the Small Molecule Discovery Center, a collaborative research and core lab that includes a high-throughput screening facility and medicinal chemistry. Dr. Arkin is a renowned expert on medicinal chemistry, chemical biology, protein-protein interactions, screening, cancer, neurodegenerative disease, and neglected diseases.